PRO4487 POLYPEPTIDES
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
1 - 28 . (canceled)
29 . An isolated polypeptide having at least 80% amino acid sequence identity to:
(a) the amino acid sequence of the polypeptide of SEQ ID NO:48;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:48, lacking its associated signal peptide;
(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number PTA-43,
wherein said polypeptide inhibits endothelial cell proliferation.
30 . An isolated polypeptide having at least 85% amino acid sequence identity to:
(a) the amino acid sequence of the polypeptide of SEQ ID NO:48;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:48, lacking its associated signal peptide;
(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number PTA-43,
wherein said polypeptide inhibits endothelial cell proliferation.
31 . An isolated polypeptide having at least 90% amino acid sequence identity to:
(a) the amino acid sequence of the polypeptide of SEQ ID NO:48;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:48, lacking its associated signal peptide;
(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number PTA-43,
wherein said polypeptide inhibits endothelial cell proliferation.
32 . An isolated polypeptide having at least 95% amino acid sequence identity to:
(a) the amino acid sequence of the polypeptide of SEQ ID NO:48;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:48, lacking its associated signal peptide;
(c) the amino acid sequence of the polypeptide encoded by the fill-length coding sequence of the cDNA deposited under ATCC accession number PTA-43,
wherein said polypeptide inhibits endothelial cell proliferation.
33 . An isolated polypeptide having at least 99% amino acid sequence identity to:
(a) the amino acid sequence of the polypeptide of SEQ ID NO,48;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:48, lacking its associated signal peptide;
(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number PTA-43,
wherein said polypeptide inhibits endothelial cell proliferation.
34 . An isolated polypeptide comprising:
(a) the amino acid sequence of the polypeptide of SEQ ID NO:48;
(b) the amino acid sequence of the polypeptide of SEQ ID NO:48, lacking its associated signal peptide;
(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number PTA-43.
35 . The isolated polypeptide of claim 34 comprising the amino acid sequence of the polypeptide of SEQ ID NO:48.
36 . The isolated polypeptide of claim 34 comprising the amino acid sequence of the polypeptide of SEQ ID NO:48, lacking its associated signal peptide.
37 . (canceled)
38 . (canceled)
39 . The isolated polypeptide of claim 34 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number PTA-43.
40 . A chimeric polypeptide comprising a polypeptide according to claim 29 fused to a heterologous polypeptide.
41 . The chimeric polypeptide of claim 40 , wherein said heterologous polypeptide is an epitope tag on an Fc region of an immunoglobulin.